跳至主要内容
临床试验/NCT06428357
NCT06428357已完成不适用

Efficacy of Recombinant Bovine Lactoferrin (rbLf) in Iron Regulation

University of North Carolina, Chapel Hill1 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2024年7月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
92
试验地点
1
主要终点
Change in serum iron (mcg/dL)

研究概览

简要总结

Overall Objective: To determine the efficacy of rbLf supplementation in a healthy adult population, specifically with regard to iron regulation (primary), gut health (secondary), and immune function (secondary). Purpose: The purpose of this study is to determine the effects of rbLf on iron regulation, exercise performance, gut health, and immune function as compared to cow's milk derived bLf.

Participants: To account for an approximate ~10% dropout rate (and rounding up to ensure equal number of enrolled participants per group), n=25 per group for males (N=50) and n=30 per group for females (N=60) will be enrolled for a total sample size of N=110.

Procedures: Participation in this study will include 6 in-person visits over 14 weeks. Anemia will be checked and excluded at the first visit using a single finger prick, followed by a 10-20 min exercise test on a treadmill to evaluate exercise capacity. On visit 2 participants will perform three 3-15 minute exercise tests on a treadmill with rest in between each test in order to determine exercise performance. A finger prick will be performed before and after each run to determine lactate levels. After visits 2 participants will be randomized to their respective supplement group recombinant Bovine Lactoferrin supplement (rbLf) (Male and Fame), a bovine-milk derived Lactoferrin supplement (Female), or a placebo (Male) once daily for 4 weeks. Blood samples will be obtained prior to and after each supplement phase to determine change in iron levels and red blood cell capacity. After a 2-week washout participants will return to complete the same testing outcomes and will receive the subsequent supplement. At visit 6 a final blood sample will be collected.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Double (Participant, Investigator)

盲法说明

Double-Blind

入排标准

年龄范围
18 Years 至 42 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •18-42 years
  • •Body mass index less than 35 kg/m^2
  • •Finger prick hemoglobin levels fitting within "normal range"
  • •Males: 14-18g/dL
  • •Females: 12-16g/dL
  • •Active: meeting American College of Sports Medicine exercise guidelines or exercising more than 2 days per week of
  • •● For females specifically:
  • •Pre-menopausal: experiencing a regular period with no signs of perimenopause or menopause.

排除标准

  • •Clinically diagnosed iron-deficiency anemia, pagophagia, hemochromatosis, or other blood or iron related medical conditions.
  • •Allergy or intolerance to milk, egg, soy, peanut, wheat, coconut, or almond dairy
  • •Smokers or vapers of nicotine or nicotine products
  • •Immunocompromised or diagnosed with Type I or II diabetes
  • •Irritable Bowel Disease, Crohn's disease, Celiacs
  • •Bowel movements less than three times per week, or clinically constipated
  • •Oral contraceptive users that have combined iron supplementation, or non-monophasic oral contraceptive users.
  • •Pregnant or nursing
  • •Chronic eczema or clinically diagnosed asthma.
  • •Current antibiotic use or antibiotic use within the past 6 weeks
  • •If flu, corona virus, or cold occurs, subject will remain in the study with their original scheduled visits, but immune values will be excluded.
  • •Vegan (due to supplement ingredients).

研究组 & 干预措施

Females: Recombinant Bovine Lactoferrin (rbLf), then Bovine milk derived Lactoferrin

Experimental

After a 2-week run-in period, this arm will begin treatment with recombinant bovine lactoferrin for 4 weeks and following a 2-week washout start bovine milk derived lactoferrin for 4 weeks.

干预措施: Recombinant Bovine Lactoferrin (Dietary Supplement)

Females: Recombinant Bovine Lactoferrin (rbLf), then Bovine milk derived Lactoferrin

Experimental

After a 2-week run-in period, this arm will begin treatment with recombinant bovine lactoferrin for 4 weeks and following a 2-week washout start bovine milk derived lactoferrin for 4 weeks.

干预措施: Bovine Milk-Derived Lactoferrin (Dietary Supplement)

Females: Bovine milk derived lactoferrin (cmdLf), then Recombinant bovine lactoferrin

Active Comparator

After a 2-week run-in period, this arm will begin treatment with bovine milk derived lactoferrin and then following a 2-week washout start recombinant bovine lactoferrin for 4 weeks.

干预措施: Recombinant Bovine Lactoferrin (Dietary Supplement)

Females: Bovine milk derived lactoferrin (cmdLf), then Recombinant bovine lactoferrin

Active Comparator

After a 2-week run-in period, this arm will begin treatment with bovine milk derived lactoferrin and then following a 2-week washout start recombinant bovine lactoferrin for 4 weeks.

干预措施: Bovine Milk-Derived Lactoferrin (Dietary Supplement)

Males: Recombinant Bovine Lactoferrin (rbLf), then placebo

Active Comparator

After a 2-week run-in period, this arm will begin treatment with recombinant bovine lactoferrin for 4 weeks and following a 2-week washout start placebo for 4 weeks.

干预措施: Recombinant Bovine Lactoferrin (Dietary Supplement)

Males: Recombinant Bovine Lactoferrin (rbLf), then placebo

Active Comparator

After a 2-week run-in period, this arm will begin treatment with recombinant bovine lactoferrin for 4 weeks and following a 2-week washout start placebo for 4 weeks.

干预措施: Placebo (Dietary Supplement)

Males: Placebo, then recombinant bovine lactoferrin (rbLf)

Placebo Comparator

After a 2-week run-in period, this arm will begin treatment with placebo for 4 weeks and following a 2-week washout start recombinant bovine lactoferrin for 4 weeks.

干预措施: Recombinant Bovine Lactoferrin (Dietary Supplement)

Males: Placebo, then recombinant bovine lactoferrin (rbLf)

Placebo Comparator

After a 2-week run-in period, this arm will begin treatment with placebo for 4 weeks and following a 2-week washout start recombinant bovine lactoferrin for 4 weeks.

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Change in serum iron (mcg/dL)

时间窗: baseline to 4 weeks

change in serum blood values obtained before and after supplementation

Change in red blood cell count (trillion cells/L)

时间窗: baseline to 4 weeks

change in blood values obtained before and after supplementation

Change in ferritin iron (ng/mL)

时间窗: baseline to 4 weeks

change in blood values obtained before and after supplementation

change in iron binding capacity (mcg/dL)

时间窗: baseline to 4 weeks

change in blood values obtained before and after supplementation

次要结局

  • change in interleukin-6 (pg/ml)(baseline to 4 weeks)
  • change on tumor necrosis factor-a (pg/mL)(baseline to 4 weeks)
  • change in time to exhaustion running (seconds)(baseline to 4 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验